±3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that enhances sociability and feelings of closeness with others. These “prosocial” effects appear to motivate the recreational use of MDMA and may also form the basis of its potential as an adjunct to psychotherapy. However, the extent to which MDMA differs from prototypic stimulant drugs, such as dextroamphetamine, methamphetamine, and methylphenidate, in either its behavioral effects or mechanisms of action, is not fully known. The purpose of this review is to evaluate human laboratory findings of the social effects of MDMA compared to other stimulants, ranging from simple subjective ratings of sociability to more complex elements of social processing and behavior. We also review the neurochemical mechanisms by which these drugs may impact sociability. Together, the findings reviewed here lay the groundwork for better understanding the socially enhancing effects of MDMA that distinguish it from other stimulant drugs, especially as these effects relate to the reinforcing and potentially therapeutic effects of the drug.
AnackerABeeryA (2013) Life in groups: the roles of oxytocin in mammalian sociality. Front Behav Neurosci7: 185.
2.
AngristBMGershonS (1970) The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. Biol Psychiatry2: 95–107.
3.
BaggottMJCoyleJRSiegristJD. (2016) Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol30: 378–387.
4.
BarchDMCarterCS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res77: 43–58.
5.
Baron-CohenSWheelwrightSHillJ. (2001) The “Reading the Mind in the Eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry42: 241–251.
6.
BattagliaGBrooksBPKulsakdinunC. (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol149: 159–163.
7.
BediGCecchiGASlezakDF. (2014) A window into the intoxicated mind? Speech as an index of psychoactive drug effects. Neuropsychopharmacology39: 2340–2348.
8.
BediGHymanDDe WitH (2010) Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry68: 1134–1140.
9.
BediGPhanKLAngstadtM. (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology207: 73–83.
10.
BershadAKKirkpatrickMGSeidenJA. (2015) Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels. J Clin Psychopharmacol35: 308–312.
BousoJCDoblinRFarreM. (2008) MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs40: 225–236.
13.
BuffumJMoserC (1986) MDMA and human sexual function. J Psychoactive Drugs18: 355–359.
14.
Carhart-HarrisRLWallMBErritzoeD. (2014) The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol17: 527–540.
15.
CarterCSGrippoAJPournajafi-NazarlooH. (2008) Oxytocin, vasopressin and sociality. Prog Brain Res170: 331–336.
16.
ChildsEBershadAKDe WitH (2016) Effects of d-amphetamine upon social stress responses. J Psychopharmacol30: 608–615.
17.
de WitHClarkMBrauerL (1997) Effects of d-amphetamine in grouped versus isolated humans. Pharmacol Biochem Behav57: 333–340.
18.
de WitHGriffithsRR (1991) Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend28: 83–111.
19.
DeltonAWRobertsonTE (2012) The social cognition of social foraging: partner selection by underlying valuation. Evol Hum Behav33: 715–725.
20.
DimbergU (1990) Facial electromyography and emotional reactions. Psychophysiology27: 481–494.
21.
DornanWAKatzJLRicaurteGA (1991) The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat. Pharmacol Biochem Behav39: 813–816.
22.
DowningJ (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs18: 335–340.
23.
DumontGJVerkesRJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol20: 176–187.
24.
DumontGKramersCSweepF. (2010) Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. J Psychopharmacol24: 165–174.
25.
DumontGJSweepFCvan der SteenR. (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci4: 359–366.
26.
DziobekIRogersKFleckS. (2008) Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET). J Autism Dev Disord38: 464–473.
27.
EllinwoodEHJrSudilovskyANelsonLM (1973) Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry130: 1088–1093.
28.
FallonJKShahDKicmanAT. (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci965: 399–409.
29.
FarréMAbanadesSRosetPN. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther323: 954.
30.
FischerHZernigGSchatzD. (2000) MDMA (“ecstasy”) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci12: 1385–1390.
31.
FleckensteinAEVolzTJRiddleEL. (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol47: 681–698.
32.
FryeCGWardleMCNormanGJ. (2014) MDMA decreases the effects of simulated social rejection. Pharmacol Biochem Behav117: 1–6.
33.
GlennonRA (1999) Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav64: 251–256.
34.
GreerGTolbertR (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs18: 319–327.
35.
GriffithsRRStitzerMCorkerK. (1977) Drug-produced changes in human social behavior: facilitation by d-amphetamine. Pharmacol Biochem Behav7: 365–372.
36.
GrinspoonLBakalarJ (1986) Can drugs be used to enhance the psychotherapeutic process?Am J Psychother40: 393–404.
37.
GudelskyGANashJF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem66: 243–249.
38.
HaberSNKnutsonB (2010) The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology35: 4–26.
39.
HaririARVenkataSMTessitoreA. (2002) Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology27: 1036–1040.
40.
HarrisDSBaggottMMendelsonJH. (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology162: 396–405.
41.
HaslerFStuderusELindnerK. (2009) Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol23: 923–935.
HigginsSTStitzerML (1989) Monologue speech: effects of d-amphetamine, secobarbital and diazepam. Pharmacol Biochem Behav34: 609–618.
44.
HuntGEMcGregorISCornishJL. (2011) MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res Bull86: 65–73.
45.
HysekCMDomesGLiechtiME (2012a) MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology (Berl)222: 293–302.
HysekCMSimmlerLDIneichenM. (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther90: 246–255.
48.
HysekCMSimmlerLDNicolaVG. (2012a) Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PloS One7: e36476.
49.
HysekCMSimmlerLDSchillingerN. (2014b) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol17: 371–381.
50.
InselTR (2010) The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron65: 768–779.
51.
JohansenPKrebsT (2009) How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol23: 389–391.
52.
JohansonCEKilbeyMGatchalianK. (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend81: 27–36.
53.
KambojSKKilfordEJMinchinS. (2015) Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or “ecstasy” and self-focused compassion: preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices. J Psychopharmacol29: 961–970.
54.
Kamilar-BrittPBediG (2015) The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev57: 433–446.
55.
KernisMHGoldmanBM (2006) A multicomponent conceptualization of authenticity: theory and research. Adv Exp Soc Psychol38: 283–357.
56.
KirkpatrickMGde WitH (2013) In the company of others: social factors alter acute alcohol effects. Psychopharmacology (Berl)230: 215–226.
57.
KirkpatrickMDeltonAWde WitH. (2015) Prosocial effects of MDMA: a measure of generosity. J Psychopharmacol29: 661–668.
58.
KirkpatrickMGBaggottMJMendelsonJE. (2014a) MDMA effects consistent across laboratories. Psychopharmacology231: 3899–3905.
59.
KirkpatrickMGGundersonEWPerezAY. (2012) A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)219: 109–122.
60.
KirkpatrickMGLeeRWardleMC. (2014b) Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology39: 1654–1663.
61.
KochSGallowayMP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm104: 135–146.
62.
KraehenmannRPrellerKHScheideggerM. (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry78: 572–581.
63.
KuypersKPdelaTorreRFarreM. (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLOS ONE9: e100719.
64.
LakeyCEKernisMHHeppnerWL. (2008) Individual differences in authenticity and mindfulness as predictors of verbal defensiveness. J Res Personality42: 230–238.
65.
LaneRDRyanLNadelL. (2014) Memory reconsolidation, emotional arousal and the process of change in psychotherapy: new insights from brain science. Behav Brain Sci1–80.
66.
LentonAPSlabuLSedikidesC. (2013) I feel good, therefore I am real: testing the causal influence of mood on state authenticity. Cogn Emot27: 1202–1224.
67.
LiCWangWSummerSN. (2008) Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol19: 225–232.
68.
LiechtiM (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly145: w14043.
69.
LiechtiMEBaumannCGammaA. (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA,“ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology22: 513–521.
70.
M ter BogtTFEngelsRC (2005) “Partying” hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse40: 1479–1502.
MaslowA (1968) Toward a Psychology of Being. New York: Van Nostrund.
73.
McElrathK (2005) MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk. Subst Use Misuse40: 1461–1477.
74.
MillerMABershadAKde WitH (2015) Drug effects on responses to emotional facial expressions: recent findings. Behav Pharmacol26: 571–579.
75.
MithoeferMWagnerMMithoeferA. (2013) Durability of improvement in PTSD symptoms and absence of harmful effects or drug dependency after MDMA-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol27: 28–39.
76.
MithoeferMCWagnerMTMithoeferAT. (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol25: 439–452.
77.
MoonNW (2009) The amphetamine years: a study of the medical applications and extramedical consumption of psychostimulant drugs in the postwar United States 1945–1980. PhD Dissertation, Georgia Institute of Technology, Atlanta, GA.
78.
NairSGGudelskyGA (2006) 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology (Berl)184: 182–189.
79.
NataleMDahlbergCJaffeJ (1979) The effect of psychotomimetics on therapist–patient matching of speech “rhythms.”J Commun Disord12: 45–52.
80.
NicholsDE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.J Psychoactive Drugs18: 305–313.
81.
NicholsDEOberlenderR (1989) Structure-activity relationships of MDMA-like substances. NIDA Res Monogr94: 1–29.
82.
OehenPTraberRWidmerV. (2013) A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol27: 40–52.
83.
PeroutkaSJNewmanHHarrisH (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology1: 273–277.
84.
PetersG-JYKokG (2009) A structured review of reasons for ecstasy use and related behaviours: pointers for future research. BMC Public Health9: 1.
85.
RamosLHicksCKevinR. (2013) Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology38: 2249–2259.
86.
RasmussenN (2008) America’s first amphetamine epidemic 1929–1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health98: 974–985.
87.
ReynoldsS (1998) Generation Ecstasy: Into the World of Techno and Rave Culture. New York, USA: Psychology Press.
88.
RogersC (1961) On Becoming a Person: A Therapist’s View of Psychotherapy. New York, USA: Houghton Mifflin Harcourt.
89.
RothmanRBBaumannMHDerschCM. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39: 32–41.
90.
RudnickGWallSC (1992) The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A89: 1817–1821.
91.
SchmidYEnzlerFGasserP. (2015a) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry78: 544–553.
92.
SchmidYHysekCMPrellerKH. (2015b) Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships. Eur Neuropsychopharmacol25: 17–25.
93.
SchmidYHysekCMSimmlerLD. (2014) Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol28: 847–856.
94.
ShulginAT (1986) The background and chemistry of MDMA. J Psychoactive Drugs18: 291–304.
95.
SiegelRK (1986) MDMA: nonmedical use and intoxication. J Psychoactive Drugs18: 349–354.
96.
SimmlerLDHysekCMLiechtiME (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab96: 2844–2850.
97.
SitteHHFreissmuthM (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci36: 41–50.
98.
StewartLFergusonBMorganC. (2014) Effects of ecstasy on cooperative behaviour and perception of trustworthiness: a naturalistic study. J Psychopharmacol28: 1001–1008.
99.
StitzerMLGriffithsRRLiebsonI (1978) Effects of d-amphetamine on speaking in isolated humans. Pharmacol Biochem Behav9: 57–63.
100.
StrakowskiSMSaxKWSettersMJ. (1996) Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry40: 872–880.
101.
SulzerDSondersMSPoulsenNW. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol75: 406–433.
102.
SumnallHRColeJCJeromeL (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol20: 670–682.
103.
TancerMJohansonCE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend72: 33–44.
104.
TancerMJohansonCE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)189: 565–573.
105.
ThompsonMRCallaghanPDHuntGE. (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience146: 509–514.
106.
Van IJzendoornMHBakermans-KranenburgMJ (2012) A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology37: 438–443.
107.
van WelJHKuypersKPTheunissenEL. (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT 2 and 5-HT 1 receptors. PLOS ONE7: e40187.
108.
VerricoCDMillerGMMadrasBK (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology189: 489–503.
109.
WardASKellyTHFoltinRW. (1997) Effects of d-amphetamine on task performance and social behavior of humans in a residential laboratory. Exp Clin Psychopharmacol5: 130.
110.
WardleMCde WitH (2012) Effects of amphetamine on reactivity to emotional stimuli. Psychopharmacology220: 143–153.
111.
WardleMCde WitH (2014) MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology231: 4219–4229.
112.
WardleMCGarnerMJMunafòMR. (2012) Amphetamine as a social drug: effects of d-amphetamine on social processing and behavior. Psychopharmacology (Berl)223: 199–210.
113.
WardleMCKirkpatrickMGde WitH (2014) “Ecstasy” as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Soc Cogn Affect Neurosci9: 1076–1081.
114.
WhalenPJRauchSLEtcoffNL. (1998) Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci18: 411–418.
115.
WilliamsKDJarvisB (2006) Cyberball: a program for use in research on interpersonal ostracism and acceptance. Behav Res Methods38: 174–180.
116.
WolffKTsapakisEMWinstockAR. (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol20: 400–410.
117.
WoodAMLinleyPAMaltbyJ. (2008) The authentic personality: a theoretical and empirical conceptualization and the development of the Authenticity Scale. J Couns Psychol55: 385–399.
118.
ZacnyJPBodkerBKde WitH (1992) Effects of setting on the subjective and behavioral effects of d-amphetamine in humans. Addict Behav17: 27–33.
119.
ZadroLWilliamsKDRichardsonR (2004) How low can you go? Ostracism by a computer is sufficient to lower self-reported levels of belonging, control, self-esteem, and meaningful existence. J Exper Soc Psychol40: 560–567.
120.
ZaldDH (2003) The human amygdala and the emotional evaluation of sensory stimuli. Brain Res Rev41: 88–123.
121.
ZemishlanyZAizenbergDWeizmanA (2001) Subjective effects of MDMA (“ecstasy”) on human sexual function. Eur Psychiatry16: 127–130.
